Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset “EL-22” For The Treatment Of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a